Detail akcie Rafael Hlds-B WI Rg online

Business Summary: Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The Company's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.
Financial Summary: BRIEF: For the three months ended 31 October 2025, Rafael Holdings Inc revenues increased 88% to $240K. Net loss increased 9% to $9.8M. Revenues reflect Real Estate segment increase of 12% to $86K. Higher net loss reflects Healthcare segment loss increase from $3.5M to $10.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.37 to -$0.19.